Petros Pharmaceuticals Share Price

Equities

PTPI

US71678J2096

Market Closed - Nasdaq 02:00:00 29/06/2024 am IST 5-day change 1st Jan Change
0.4575 USD +2.69% Intraday chart for Petros Pharmaceuticals +12.16% -67.55%
Sales 2024 * 5.41M 451M Sales 2025 * 5.48M 456M Capitalization 3.2M 267M
Net income 2024 * -19M -1.58B Net income 2025 * -15M -1.25B EV / Sales 2024 * 0.59 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.58 x
P/E ratio 2024 *
-0.11 x
P/E ratio 2025 *
-0.14 x
Employees 21
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) OTC Switch CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading MT
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication MT
Lemonaid Health, Inc. Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals CI
Petros, Lemonaid Health Collaborate to Expand Stendra Availability MT
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health CI
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process MT
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R) CI
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider CI
Top Premarket Gainers MT
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study CI
More news
1 day+2.69%
1 week+12.16%
Current month-25.51%
1 month-25.74%
3 months-69.09%
6 months-67.55%
Current year-67.55%
More quotes
1 week
0.41
Extreme 0.4081
0.51
1 month
0.39
Extreme 0.385
0.65
Current year
0.39
Extreme 0.385
2.27
1 year
0.39
Extreme 0.385
4.74
3 years
0.39
Extreme 0.385
52.00
5 years
0.39
Extreme 0.385
59.60
10 years
0.39
Extreme 0.385
59.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 -
President 47 01/20/01
Comptroller/Controller/Auditor 61 01/19/01
Members of the board TitleAgeSince
Chief Executive Officer 61 -
Director/Board Member 60 01/20/01
Director/Board Member 54 01/20/01
More insiders
Date Price Change Volume
28/24/28 0.4575 +2.69% 174,869
27/24/27 0.4455 +1.60% 222,387
26/24/26 0.4385 -8.65% 451,484
25/24/25 0.48 +7.87% 2,183,190
24/24/24 0.445 +9.10% 340,822

Delayed Quote Nasdaq, June 29, 2024 at 02:00 am IST

More quotes
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.
Sector
-
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.4575 USD
Average target price
4 USD
Spread / Average Target
+774.32%
Consensus